MoonLake Immunotherapeutics SEC filings MLTX
MoonLake Immunotherapeutics has 331 filings in SEC EDGAR's recent list, going back to Aug 28, 2020. Its latest annual report, Form ARS, was filed on Apr 21, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| UPLOAD | Letter from the SEC | May 13, 2024 | — |
| CORRESP | Letter to the SEC | May 7, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 29, 2024 | — |
| EFFECT | Filing | Sep 11, 2023 | — |
| CORRESP | Letter to the SEC | Sep 7, 2023 | — |
| UPLOAD | Letter from the SEC | Sep 6, 2023 | — |
| EFFECT | Filing | May 9, 2023 | — |
| CORRESP | Letter to the SEC | May 5, 2023 | — |
| EFFECT | Filing | May 4, 2023 | — |
| UPLOAD | Letter from the SEC | May 4, 2023 | — |
| EFFECT | Filing | Mar 27, 2023 | — |
| EFFECT | Filing | Aug 2, 2022 | — |
| CORRESP | Letter to the SEC | Jul 29, 2022 | — |
| CORRESP | Letter to the SEC | Jul 26, 2022 | — |
| UPLOAD | Letter from the SEC | Jul 21, 2022 | — |
| CORRESP | Letter to the SEC | Jul 15, 2022 | — |
| UPLOAD | Letter from the SEC | May 16, 2022 | — |
| 425 | Current report | Mar 24, 2022 | — |
| DEFR14A | Proxy statement | Mar 4, 2022 | — |
| UPLOAD | Letter from the SEC | Feb 11, 2022 | — |
| CORRESP | Letter to the SEC | Feb 11, 2022 | — |
| PRER14A | Preliminary revised proxy materials | Feb 11, 2022 | — |
| UPLOAD | Letter from the SEC | Feb 10, 2022 | — |
| CORRESP | Letter to the SEC | Feb 3, 2022 | — |
| PRER14A | Proxy statement | Feb 3, 2022 | — |
| UPLOAD | Letter from the SEC | Feb 2, 2022 | — |
| PRER14A | Proxy statement | Jan 21, 2022 | — |
| CORRESP | Letter to the SEC | Jan 20, 2022 | — |
| UPLOAD | Letter from the SEC | Jan 12, 2022 | — |
| UPLOAD | Letter from the SEC | Jan 12, 2022 | — |
| PRER14A | Proxy statement | Dec 16, 2021 | — |
| CORRESP | Letter to the SEC | Dec 15, 2021 | — |
| CORRESP | Letter to the SEC | Dec 14, 2021 | — |
| UPLOAD | Letter from the SEC | Nov 24, 2021 | — |
| UPLOAD | Letter from the SEC | Nov 24, 2021 | — |
| NT 10-Q | Notification of late filing | May 18, 2021 | Mar 31, 2021 |
| CERT | Filing | Oct 20, 2020 | — |
| EFFECT | Filing | Oct 19, 2020 | — |
| 8-A12B | For registration of certain classes | Oct 19, 2020 | — |
| CORRESP | Letter to the SEC | Oct 15, 2020 | — |
| CORRESP | Letter to the SEC | Oct 15, 2020 | — |
| CORRESP | Letter to the SEC | Oct 1, 2020 | — |
| UPLOAD | Letter from the SEC | Sep 24, 2020 | — |
| DRS | Filing | Aug 28, 2020 | — |
Showing 44 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MLTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Zug, Switzerland
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1821586
- Former names
- Helix Acquisition Corp (until Mar 31, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.